Leerink Partnrs Has Bearish Outlook for EW Q4 Earnings

Edwards Lifesciences Corporation (NYSE:EW) – Analysts at Leerink Partnrs dropped their Q4 2025 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a research note issued to investors on Friday, July 25th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will post earnings per share of $0.57 for the quarter, down from their prior forecast of $0.63. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2026 earnings at $2.80 EPS, FY2027 earnings at $3.28 EPS, FY2028 earnings at $3.75 EPS and FY2029 earnings at $4.24 EPS.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. The business had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the business posted $0.70 EPS. The business’s quarterly revenue was up 11.9% compared to the same quarter last year.

Several other research analysts have also commented on EW. Citigroup reaffirmed a “buy” rating and set a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a research report on Friday. Dbs Bank raised Edwards Lifesciences to a “hold” rating in a research report on Monday, June 2nd. Argus raised Edwards Lifesciences to a “strong-buy” rating in a research report on Thursday, July 10th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $85.00.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $79.92 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. Edwards Lifesciences has a fifty-two week low of $59.41 and a fifty-two week high of $83.00. The firm has a market capitalization of $46.88 billion, a PE ratio of 11.50, a price-to-earnings-growth ratio of 4.00 and a beta of 1.11. The stock’s 50-day simple moving average is $76.58 and its 200-day simple moving average is $73.55.

Insider Transactions at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 5,980 shares of Edwards Lifesciences stock in a transaction on Monday, May 5th. The stock was sold at an average price of $74.91, for a total transaction of $447,961.80. Following the transaction, the chief executive officer directly owned 58,284 shares in the company, valued at approximately $4,366,054.44. This trade represents a 9.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the transaction, the insider owned 206,900 shares in the company, valued at approximately $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,848 shares of company stock worth $2,314,488 over the last quarter. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds have recently modified their holdings of EW. Vega Investment Solutions acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $27,000. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences in the first quarter worth $26,000. SouthState Corp acquired a new stake in shares of Edwards Lifesciences in the first quarter worth $27,000. Rossby Financial LCC acquired a new stake in Edwards Lifesciences during the first quarter valued at $29,000. Finally, Costello Asset Management INC acquired a new stake in Edwards Lifesciences during the first quarter valued at $29,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.